Skip to main content
OpenTrials

Clinical trial condition

Gram-Negative Bacterial Infections

Explore clinical trials studying Gram-Negative Bacterial Infections. Study availability and eligibility vary by location and protocol.

1,462 public trials 132 recruiting studies
Refine in advanced search Browse all conditions

Gram-Negative Bacterial Infections trial results

Completed

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

NCT02285777

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Melbourne, Florida, United States
  • GSK Investigational Site Newton, Kansas, United States
View Trial Details
Completed

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Dothan, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
View all 56 locations
View Trial Details
Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

NCT01766206

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Ansan, South Korea
  • GSK Investigational Site Anyang, South Korea
  • GSK Investigational Site Bucheon-si, South Korea
  • GSK Investigational Site Busan, South Korea
View all 54 locations
View Trial Details
Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

NCT01978093

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Fayetteville, Arkansas, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Fresno, California, United States
View all 26 locations
View Trial Details
Completed

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

NCT02140762

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Accelovance, Inc Huntsville, Alabama, United States
  • The Children's Clinic of Jonesboro, P.A. Jonesboro, Arkansas, United States
  • Accelovance, Inc Melbourne, Florida, United States
  • Heartland Research Associates LLC Newton, Kansas, United States
View Trial Details
Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

NCT00129116

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Asse, Belgium
  • GSK Investigational Site Drongen, Belgium
  • GSK Investigational Site Ghent, Belgium
  • GSK Investigational Site Maldegem, Belgium
View all 26 locations
View Trial Details

Related conditions